Press release
Pancreatic Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
DelveInsight's "Pancreatic Cancer Pipeline Insight, 2025," report provides comprehensive insights about 170+ companies and 200+ pipeline drugs in Pthe ancreatic Cancer pipeline landscape. It covers the Pancreatic Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pancreatic Cancer Pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Pancreatic Cancer Pipeline Report to explore emerging therapies, key Pancreatic Cancer Companies, and future Pancreatic Cancer treatment landscapes @ Pancreatic Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Pancreatic Cancer Pipeline Report
* On 28 August 2025, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins announced a Phase 2 Study of NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Treatment-naive, Metastatic Pancreatic Cancer.
* On 27 August 2025, Joseph J. Cullen conducted a study adds 75 grams of ascorbate (vitamin C, sometimes called pharamcological ascorbate because the dose is so high) to standard therapy. The ascorbate is administered intravenously - through a vein in the arm.
* On 26 August 2025, Ruijin Hospital organized study is an open, single center, exploratory clinical trial aimed at evaluating the safety and efficacy of HRS-4642 in combination with gemcitabine and albumin-bound paclitaxel for neoadjuvant and adjuvant treatment of pancreatic cancer.
* DelveInsight's Pancreatic Cancer pipeline report depicts a robust space with 170+ active players working to develop 200+ pipeline therapies for Pancreatic Cancer treatment.
* The leading Pancreatic Cancer Companies such as Fibrogen, AB Science, Eleison Pharmaceuticals LLC, Janssen Pharmaceuticals, CARsgen Therapeutics, Arcus Biosciences, Inc., Chia Tai Tianqing Pharmaceutical Group, Innovent Biologics, Amgen, Biomea Fusion, Prestige Biopharma Limited, Bristol-Myers Squibb, GlaxoSmithKline, Incyte Corporation, Helix BioPharma, Genentech, Inc., ENB Therapeutics, Carrick Therapeutics, Avenge Bio, DEKA Biosciences, Keymed Biosciences, Pfizer, Redx Pharma Plc, and AIM ImmunoTech Inc. , and others.
* Promising Pancreatic Cancer Pipeline Therapies such as Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004), and Gemcitabine , and others.
Stay ahead with the most recent pipeline outlook for Pancreatic Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pancreatic Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Pancreatic Cancer Emerging Drugs Profile
* Pamrevlumab: FibroGen
Pamrevlumab is a potential first-in-class antibody being developed by FibroGen that inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. The U.S. Food and Drug Administration has granted Orphan Drug Designation, and Fast Track designation to Pamrevlumab for the treatment of patients with pancreatic cancer. Currently it is in Phase III stage of clinical trial evaluation to treat Pancreatic Cancer.
* Masitinib: AB Science
Masitinib (AB-1010) is an investigational drug for the treatment of metastatic pancreatic cancer. The drug candidate is administered orally. It is an ATP-binding site competitor. The drug candidate acts by inhibiting wild-type forms of c-KIT, Fyn, Lyn tyrosine kinase and platelet-derived growth factor receptor alpha and beta. Masitinib is a selective inhibitor of the tyrosine kinase inhibitor that targets KIT. Currently being evaluated in the Phase III studies.
* Glufosfamide: Eleison Pharmaceuticals LLC.
Glufosfamide combines the active part of ifosfamide, a member of a widely used class of chemotherapy drugs called as alkylators with a glucose molecule. Because of its glucose component and a tumor cell's increased need for glucose, glufosfamide may be preferentially transported into tumors compared to most normal tissues. Inside cells, the linkage between glucose and the alkylator is cleaved to release the active drug. Currently the drug is being evaluated in Phase III for the treatment of Pancreatic Cancer.
* Quemliclustat: Arcus Biosciences, Inc.
Quemliclustat is a potent and selective small molecule being developed by Arcus Biosciences. Inhibitor of CD73 that has been shown to block the production of adenosine. The reduction of adenosine restores immune function. The drug candidate is administered through intravenous and oral route. The drug candidate is currently in Phase III stage of clinical trial.
* CT041: CARsgen Therapeutics
CT041 is a potential first in class autologous chimeric antigen receptor CAR T-cell product candidate that targets the protein CLDN18.2. CT041 targets the treatment of CLDN18.2 positive solid tumors with a primary focus on pancreatic cancer. The drug candidate presently is in Phase II stage.
* DK210: DEKA Biosciences
DK210 (EGFR) is the first of several experimental therapeutics developed as part of Deka's platform of molecules, which combines the cytokines full strength IL-2 and a high affinity IL-10. While IL-2 is known to be toxic, when coupled with IL-10, toxicity is not only reduced but its potency is increased, thereby creating a more tolerable and effective treatment for patients. It is the first of several experimental therapeutics in Deka's platform of molecules which are being developed to treat both cancer and inflammatory diseases. These therapeutics, known as DiakinesTM, involve coupling two cytokines together onto a single chain variable fragment (scFv) targeting system to enhance their precision in targeting specific tissues. Furthermore, the scFv scaffold used in the DiakineTM platform also improves efficacy, safety and manufacturability of each treatment. The drug candidate presently is in Phase I stage for the treatment of pancreatic cancer.
* CT7001: Carrick Therapeutics
Samuraciclib is the most advanced CDK7 inhibitor in clinical development. Inhibiting CDK7 is a promising therapeutic strategy in cancer as CDK7 regulates the transcription of cancer-causing genes, promotes uncontrolled cell cycle progression and promotes resistance to anti-hormone therapy. Samuraciclib has demonstrated a favorable safety profile and encouraging efficacy in early clinical studies. In addition to the above studies, samuraciclib has further potential in prostate, pancreatic, ovarian and colorectal cancers. Samuraciclib has been granted Fast Track designation from the U.S. Food and Drug Administration (FDA) for use in combination with fulvestrant for the treatment of CDK4/6i resistant HR+, HER2- advanced breast cancer. Carrick is collaborating with Roche, Menarini Group and Arvinas/Pfizer to evaluate novel combinations of samuraciclib with Roche's oral SERD giredestrant, Menarini Group's oral SERD elacestrant, and Arvinas/Pfizer's proteolysis targeting chimera (PROTAC) Estrogen Receptor degrader vepdegestrant (ARV-471) in late-stage CDK4/6i resistant HR+, HER2- metastatic breast cancer. Currently the drug is in preclinical stage of its development for the treatment of pancreatic cancer.
The Pancreatic Cancer Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Cancer treatment.
* Pancreatic Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Pancreatic Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Cancer market.
Explore groundbreaking therapies and clinical trials in the Pancreatic Cancer Pipeline. Access DelveInsight's detailed report now! @ New Pancreatic Cancer Drugs [https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Pancreatic Cancer Companies
Fibrogen, AB Science, Eleison Pharmaceuticals LLC, Janssen Pharmaceuticals, CARsgen Therapeutics, Arcus Biosciences, Inc., Chia Tai Tianqing Pharmaceutical Group, Innovent Biologics, Amgen, Biomea Fusion, Prestige Biopharma Limited, Bristol-Myers Squibb, GlaxoSmithKline, Incyte Corporation, Helix BioPharma, Genentech, Inc., ENB Therapeutics, Carrick Therapeutics, Avenge Bio, DEKA Biosciences, Keymed Biosciences, Pfizer, Redx Pharma Plc, and AIM ImmunoTech Inc. , and others
Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Pancreatic Cancer Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Pancreatic Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Pancreatic Cancer Market Drivers and Barriers [https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Pancreatic Cancer Pipeline Report
* Coverage- Global
* Pancreatic Cancer Companies- Fibrogen, AB Science, Eleison Pharmaceuticals LLC, Janssen Pharmaceuticals, CARsgen Therapeutics, Arcus Biosciences, Inc., Chia Tai Tianqing Pharmaceutical Group, Innovent Biologics, Amgen, Biomea Fusion, Prestige Biopharma Limited, Bristol-Myers Squibb, GlaxoSmithKline, Incyte Corporation, Helix BioPharma, Genentech, Inc., ENB Therapeutics, Carrick Therapeutics, Avenge Bio, DEKA Biosciences, Keymed Biosciences, Pfizer, Redx Pharma Plc, and AIM ImmunoTech Inc. , and others.
* Pancreatic Cancer Pipeline Therapies- Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine , and others.
* Pancreatic Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Pancreatic Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Pancreatic Cancer drug development? Find out in DelveInsight's exclusive Pancreatic Cancer Pipeline Report-access it now! @ Pancreatic Cancer Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Pancreatic Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Pancreatic Cancer - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Pamrevlumab: FibroGen
* Drug profiles in the detailed report.....
* Mid-Stage Products (Phase II)
* CT041: CARsgen Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* DK210: DEKA Biosciences
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Pancreatic Cancer Key Companies
* Pancreatic Cancer Key Products
* Pancreatic Cancer- Unmet Needs
* Pancreatic Cancer- Market Drivers and Barriers
* Pancreatic Cancer- Future Perspectives and Conclusion
* Pancreatic Cancer Analyst Views
* Pancreatic Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pancreatic-cancer-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pancreatic Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4165715 • Views: …
More Releases from ABNewswire
Checkpoint Inhibitors Competitive Landscape & Pipeline 2025: Emerging Therapies, …
DelveInsight's, "Checkpoint Inhibitors Competitive landscape 2025" report provides comprehensive insights about 50+ companies and 60+ drugs in Checkpoint Inhibitors Competitive landscape. It covers the Checkpoint Inhibitors Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the full insights into the evolving Checkpoint Inhibitors Pipeline and discover which companies are leading the innovation race @ Checkpoint Inhibitors Competitive…
IBN Technologies' Payroll Outsourcing Services Assist U.S. Companies Optimize Op …
IBN Technologies provides payroll outsourcing services that streamline operations, improve accuracy, and ensure compliance for U.S. businesses. By reducing internal workloads and integrating with financial systems, their solutions cut costs, enhance efficiency, and support scalability. Trusted by growing enterprises, IBN simplifies payroll while enabling teams to focus on long-term goals.
Miami, Florida, 01 Sep 2025 Many operational teams are enhancing their internal structure to match performance goals with dependable processes. One…
IBN Technologies Expands Online Payroll Services for U.S. Businesses
IBN Technologies offers secure, scalable online payroll services that help U.S. businesses boost accuracy, ensure compliance, and reduce administrative burden. With seamless HR and accounting integration, automated tax filing, and real-time access, firms achieve efficiency and cost savings while improving employee satisfaction. A trusted partner for payroll success.
Miami, Florida, 01 Sep 2025 Online payroll providers are becoming essential for guaranteeing accurate and effective payroll management as American businesses continue to…
Electric Vehicle Battery Management System Market to Reach USD 42.41 Billion by …
Mordor Intelligence has published a latest report on the Electric Vehicle Battery Management System Market, offering a comprehensive analysis of trends, growth drivers, and future projections.
Introduction
Mordor Intelligence, in its latest Electric Vehicle Battery Management System Market report, forecasts that the market size is estimated at USD 16.17 billion in 2025 and expected to reach USD 42.41 billion by 2030, at a 21.27 % CAGR
The Electric Vehicle Battery Management System…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
